IQVIA (NYSE:IQV) Releases FY 2026 Earnings Guidance

IQVIA (NYSE:IQV) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 12.800-13.000 for the period, compared to the consensus EPS estimate of 12.570. The company issued revenue guidance of $17.3 billion-$17.5 billion, compared to the consensus revenue estimate of $17.3 billion.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Robert W. Baird boosted their price target on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. TD Cowen increased their target price on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Mizuho lifted their price target on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Stock Performance

Shares of IQV traded down $9.32 during mid-day trading on Thursday, hitting $238.24. The stock had a trading volume of 143,367 shares, compared to its average volume of 1,807,440. The company has a market cap of $39.76 billion, a PE ratio of 29.57, a PEG ratio of 2.18 and a beta of 1.20. The company’s fifty day simple moving average is $192.00 and its two-hundred day simple moving average is $186.89. The company has a quick ratio of 0.75, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA has a fifty-two week low of $154.50 and a fifty-two week high of $251.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts expect that IQVIA will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

Trending Headlines about IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q2 earnings beat expectations: IQVIA reported adjusted earnings of $3.15 per share, above the $3.03 consensus estimate, while revenue rose 8.7% year over year to $4.37 billion, exceeding expectations of $4.30 billion. IQVIA Holdings Inc. Q2 2026 Earnings Call Summary
• Positive Sentiment: Raised 2026 outlook and strong demand: Management increased its full-year profit guidance to $12.80-$13.00 per share, citing broad-based growth, clinical-research demand and record research-and-development bookings. A growing backlog also supports future revenue visibility. IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised
• Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $285 from $225 and assigned an overweight rating; Stifel raised its target to $276 from $220 with a buy rating; and Baird increased its target to $287 from $252 with an outperform rating. These revisions indicate additional perceived upside despite the recent rally. IQVIA Receives Consensus Rating of Moderate Buy
• Neutral Sentiment: Valuation and estimates remain considerations: IQVIA carries a consensus “Moderate Buy” rating, but analyst fair-value changes were mixed. With the stock near its 52-week high and trading at a relatively elevated earnings multiple, further gains may depend on continued execution against the upgraded outlook. IQVIA Stock Sees Modest Fair Value Lift After Mixed Analyst Target Changes

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IQV. Boston Partners acquired a new position in IQVIA during the 3rd quarter valued at about $676,698,000. Orbis Allan Gray Ltd increased its holdings in shares of IQVIA by 96.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock valued at $428,525,000 after buying an additional 933,554 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares during the period. Viking Global Investors LP bought a new stake in shares of IQVIA in the 4th quarter valued at approximately $139,582,000. Finally, FIL Ltd lifted its holdings in IQVIA by 76.7% in the 4th quarter. FIL Ltd now owns 1,063,236 shares of the medical research company’s stock worth $239,664,000 after purchasing an additional 461,614 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.